Potential Pfizer-AstraZeneca deal points to continued high valuations of biotechs
April 28, 2014 at 14:26 PM EDT
What Pfizer’s $100 billion bid to buy AstraZeneca means for Massachusetts biotech companies extends beyond the local research facilities both companies have around here...
